What are the implications of MLH1 deficiency for treatment?
The identification of MLH1 deficiency has significant implications for treatment. For instance, tumors with MSI-high (MSI-H) due to MLH1 deficiency often respond better to immunotherapy with checkpoint inhibitors like pembrolizumab. Moreover, knowing a patient's MLH1 status can guide the decision-making process regarding chemotherapy and surveillance strategies.
